GNLX
Genelux Corporation
$4.31
-$0.09(-2.05%)
29
Overall
40
Value
20
Tech
28
Quality
Market Cap
$172.37M
Volume
102.15K
52W Range
$1.99 - $8.54
Target Price
$19.00
Company Overview
| Mkt Cap | $172.37M | Price | $4.31 |
| Volume | 102.15K | Change | -2.05% |
| P/E Ratio | -5.8 | Open | $4.40 |
| Revenue | $8.0K | Prev Close | $4.40 |
| Net Income | $-29.9M | 52W Range | $1.99 - $8.54 |
| Div Yield | N/A | Target | $19.00 |
| Overall | 29 | Value | 40 |
| Quality | 28 | Technical | 20 |
No chart data available
About Genelux Corporation
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Latest News
Lake Street Sticks to Their Buy Rating for Genelux Corp. (GNLX)
TipRanks Auto-Generated Intelligence Newsdesk•5 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | GNLX | $4.31 | -2.0% | 102.15K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |